免疫學研究所醫學系皮膚科LIN, BO-SHIOUBO-SHIOULINTSAI, PEI-YUNPEI-YUNTSAIHSIEH, WAN-YUNWAN-YUNHSIEHTSAO, HSIAO-WEIHSIAO-WEITSAOLIU, MENG-WEIMENG-WEILIUWANG, LI-FANGLI-FANGWANGMIAW, SHI-CHUENSHI-CHUENMIAW林伯修蔡佩芸謝婉云曹孝瑋劉夢薇王莉芳繆希椿2011-04-282018-07-092011-04-282018-07-092010-01http://ntur.lib.ntu.edu.tw//handle/246246/233060The function of transcription factors can be critically regulated by SUMOylation. c-Maf, the cellular counterpart of v-maf oncogene, is a potent transactivator of the IL-4 gene in Th2 cells. We found in a yeast two-hybrid screen that c- Maf can interact with Ubc9 and PIAS1, two key enzymes of the SUMOylation pathway. In this study, we report that c-Maf co-localized with these two SUMO (small ubiquitin-like modifier) ligases in the nucleus and that c-Maf can be SUMOylated in vitro and also in primary Th2 cells. We also demonstrated that lysine-33 is the dominant, if not the only , SUMO acceptor site of c-Maf. SUMOylation of c-Maf attenuated its transcriptional activity. Reciprocally, a SUMOylation resistant c-Maf was more potent than WT-c-Maf in driving IL-4 production in c-Maf-deficient Th2 cells. Furthermore, we showed that ablation of the SUMO site did not alter the subcellular localization or the stability of c -Maf protein but instead enhanced its recruitment to the I14 -promoter. We conclude that SUMOylation at lysine-33 is a functionally critical post-translational modification event of c-Maf in Th cells.500627 bytesapplication/pdfen-UShttp://ntur.lib.ntu.edu.tw/bitstream/246246/233060/1/SUMOylation-c Maf-EJI-2010.pdf